Edition:
United States

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

14.43USD
22 Feb 2019
Change (% chg)

$0.17 (+1.19%)
Prev Close
$14.26
Open
$14.26
Day's High
$14.53
Day's Low
$14.26
Volume
8,664
Avg. Vol
29,316
52-wk High
$29.05
52-wk Low
$11.10

Latest Key Developments (Source: Significant Developments)

Xoma Says May Sell Shares Of Up To $30 Mln From Time To Time
Tuesday, 18 Dec 2018 05:01pm EST 

Dec 18 (Reuters) - XOMA Corp ::XOMA CORP - MAY OFFER AND SELL SHARES OF CO'S COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $30 MILLION FROM TIME TO TIME - SEC FILING.  Full Article

Xoma Announces Proposed Rights Offering
Wednesday, 7 Nov 2018 07:05am EST 

Nov 7 (Reuters) - XOMA Corp ::XOMA ANNOUNCES PROPOSED RIGHTS OFFERING.XOMA CORP - RIGHTS OFFERING WILL BE AVAILABLE TO ALL SHAREHOLDERS OF RECORD ON NOVEMBER 16, 2018.XOMA CORP - $20 MILLION TO BE RAISED.XOMA - SUBSCRIPTION RIGHTS TO HOLDERS OF COMMON STOCK, SERIES X PREFERRED STOCK, ENTITLING HOLDERS TO PURCHASE COMMON SHARES AT $13/SHARE.  Full Article

Xoma Qtrly Net Loss Per Share $0.55
Wednesday, 7 Nov 2018 07:00am EST 

Nov 7 (Reuters) - XOMA Corp ::XOMA REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 REVENUE $900,000 VERSUS $36.2 MILLION.Q3 REVENUE VIEW $3.9 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NET LOSS PER SHARE $0.55.  Full Article

Xoma Acquires Royalty Interest Position From Agenus
Friday, 21 Sep 2018 07:00am EDT 

Sept 21 (Reuters) - XOMA Corp ::XOMA ACQUIRES ROYALTY INTEREST POSITION FROM AGENUS ON SEVEN ASSETS BEING DEVELOPED BY MERCK AND INCYTE.XOMA - FOR $15.0 MILLION, GOT FROM AGENUS PARTIAL INTEREST POSITION IN RIGHTS TO POTENTIAL MILESTONE & ROYALTY PAYMENTS WITH 7 IMMUNO-ONCOLOGY ANTIBODIES.XOMA CORP - UNDER TERMS OF AGREEMENT, XOMA WILL RECEIVE LOW- TO MID-SINGLE-DIGIT ROYALTIES ON FUTURE SALES OF THESE SEVEN IMMUNO-ONCOLOGY ASSETS.XOMA CORP - ADDITIONALLY, XOMA IS ENTITLED TO A PORTION OF MILESTONE PAYMENTS ASSOCIATED WITH IMMUNO-ONCOLOGY ASSETS.XOMA CORP - HAS DRAWN $7.5 MILLION FROM ITS LINE OF CREDIT TO PARTIALLY FUND TRANSACTION.  Full Article

XOMA Reports Qtrly Loss Per Share $0.46
Wednesday, 9 May 2018 04:05pm EDT 

May 9 (Reuters) - XOMA Corp ::XOMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 REVENUE $500,000 VERSUS $300,000.Q1 REVENUE VIEW $2.7 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY LOSS PER SHARE $0.46.  Full Article

XOMA Announces Exclusive License Agreement For XOMA 358 With Rezolute Inc.
Thursday, 7 Dec 2017 08:35am EST 

Dec 7 (Reuters) - XOMA Corp ::XOMA ANNOUNCES EXCLUSIVE LICENSE AGREEMENT FOR XOMA 358 WITH REZOLUTE, INC..XOMA CORP - UNDER LICENSE AGREEMENT, CO IS ENTITLED TO RECEIVE UP TO APPROXIMATELY $240 MILLION IN EXCHANGE FOR GLOBAL XOMA 358 RIGHTS.XOMA CORP - TO RECEIVE PAYMENTS AS REZOLUTE ACHIEVES SPECIFIC MILESTONES ASSOCIATED WITH FINANCING ACTIVITIES, CLINICAL DEVELOPMENT SUCCESS​, OTHERS.XOMA-‍TERMS OF AGREEMENT INCLUDE ALLOCATION OF $5 MILLION IN SHARES OF REZOLUTE TO CO,$13 MILLION IN CASH,STOCK TO BE PAID AS REZOLUTE COMPLETES SOME MILESTONES​.XOMA SAYS IS ALSO ENTITLED TO RECEIVE LOW SINGLE-DIGIT ROYALTIES ON NET SALES OF AB101, OTHER PRODUCTS DEVELOPED FROM CERTAIN OF REZOLUTE PLATFORMS.XOMA CORP - REZOLUTE IS RESPONSIBLE FOR ALL DEVELOPMENT, REGULATORY, MANUFACTURING AND COMMERCIALIZATION ACTIVITIES UNDER LICENSE.XOMA SAYS REZOLUTE PLANS TO ADVANCE XOMA 358'S CLINICAL DEVELOPMENT IN 2018.XOMA CORP - ELIGIBLE TO RECEIVE ROYALTIES RANGING FROM HIGH SINGLE-DIGITS TO MID-TEENS ON NET SALES OF XOMA 358.  Full Article

Xoma posts Q3 revenue of $36.2 million
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Xoma Corp :Xoma reports third quarter 2017 financial results.Q3 revenue $36.2 million versus $600,000.Q3 revenue view $690,000 -- Thomson Reuters I/B/E/S.Qtrly diluted net income per share available to common stockholders $1.98.  Full Article